Медицинская библиотека · Multiple sclerosis and related disorders · 2018

Tocilizumab in MOG-antibody spectrum disorder: a case report.

Novi G, Gastaldi M, Franciotta D, Pesce G, Benedetti L, Uccelli A

Клинический случайСтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Myelin oligodendrocyte glycoprotein antibody-related spectrum disorders (MOG-SD) are a heterogeneous group of inflammatory demyelinating diseases of the central nervous system, usually responsive to conventional immunosuppressive therapies. However, knowledge about treatment of non-responder patients is scarce.

METHODS

We report on a 20-year-old MOG-SD patient who experienced clinical deterioration despite rituximab-induced B-cell depletion.

RESULTS

Rescue therapy with tocilizumab (TCZ) prevented further relapses, with reduction of spinal-cord load on MRI, and a remarkable reduction of disability at the two-year follow-up.

CONCLUSION

Our observations suggest that TCZ could induce clinico-radiologic improvements, which make it as an option for the treatment of MOG-SD.

Для цитирования: Novi G, Gastaldi M, Franciotta D, Pesce G, Benedetti L, Uccelli A. Tocilizumab in MOG-antibody spectrum disorder: a case report.. Multiple sclerosis and related disorders. 2018. DOI: 10.1016/j.msard.2018.11.012.

Предметные рубрики MeSH

Antibodies, Monoclonal, Humanized Demyelinating Autoimmune Diseases, CNS Humans Immunologic Factors Male Myelin-Oligodendrocyte Glycoprotein Optic Neuritis Rituximab Spinal Cord Treatment Outcome Young Adult

Подготовка и перевод публикации

Обработка статьи · этапы, ошибки и управление

Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.